Partnership / Collaboration · GCC · Announced 22 Oct 2026
Miltenyi Biomedicine → Abu Dhabi Stem Cells Center
Partnership / Collaboration deal between Miltenyi Biomedicine (Germany) and Abu Dhabi Stem Cells Center (United Arab Emirates), announced 22 Oct 2026.
Parties: Miltenyi Biomedicine GmbH (Germany) → Abu Dhabi Stem Cells Center (ADSCC) (United Arab Emirates)
- Deal type
- Partnership / Collaboration
- Value
- Not stated
- Territory
- UAE (development and local manufacturing); stated goal of a first regional access point for locally developed CAR-T therapies
- Therapeutic area
- Oncology
- Asset
- CAR-T cell therapies — Miltenyi provides scientific and technical support on its viral vector and anti-CD19 CAR technologies; ADSCC contributes cell therapy development and manufacturing; exploration of CAR-T beyond blood cancers into autoimmune diseases
- Announced
- 22 Oct 2026
Our analysis
Why this matters
The UAE's localization wave has reached its hardest rung: autologous cell therapy. ADSCC — already the UAE's first CAR-T manufacturer (producing since 2023) — signed with Germany's Miltenyi Biomedicine to develop and locally manufacture CAR-T, with the stated goal of a first regional access point for locally developed therapies.
For CEOs: Abu Dhabi is now competing for advanced-therapy investment, not just pharma plants.
The full analysis is free to read with a work email on this page.
Source: WAM